Other News To Note
Monday, June 4, 2012
Avanir Pharmaceuticals Inc., of Aliso Viejo, Calif., reported preliminary results from the PRISM patient registry to define pseudobulbar affect (PBA) prevalence and its quality-of-life impact, with results from the 3,647 patients with underlying neurologic conditions Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, stroke and traumatic brain injury showing that 37.3 percent had a positive screening score for PBA.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.